Anti-OASL Antibody (C-term)

2-prime,5-prime oligoadenylates (2-5As) bind to and activate RNase L, leading to degradation of RNA and inhibition of protein synthesis. 2-5As are produced by 2-5A synthetases (OASs), a highly-conserved family of interferon-induced enzymes. The predicted 514-amino acid human p59OASL (2-5A synthetases-like) protein shares a highly conserved N-terminal domain with other OASs. The C-terminal portion of p59OASL contains 2 ubiquitin-like domains. p59OASL is expressed in most tissues, with the highest levels in hematopoietic tissues, colon, and stomach.

2'-5'-oligoadenylate synthase-like protein, 2'-5'-OAS-related protein, 2'-5'-OAS-RP, 59 kDa 2'-5'-oligoadenylate synthase-like protein, Thyroid receptor-interacting protein 14, TR-interacting protein 14, TRIP-14, p59 OASL, p59OASL, OASL, TRIP14

This OASL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 484-514 amino acids from the C-terminal region of human OASL.

Expressed in most tissues, with the highest levels in primary blood Leukocytes and other hematopoietic system tissues, colon, stomach and to some extent in testis

Does not have 2'-5'-OAS activity, but can bind double- stranded RNA. Displays antiviral activity against encephalomyocarditis virus (EMCV) and hepatitis C virus (HCV) via an alternative antiviral pathway independent of RNase L.